STOK
NASDAQStoke Therapeutics Inc.
News · 26 weeks82+88%
2026-03-012026-08-23
Mix3790d
- Insider17(46%)
- Other8(22%)
- SEC Filings7(19%)
- Analyst2(5%)
- Earnings2(5%)
- Leadership1(3%)
Latest news
25 items- ANALYSTAnalyst resumed coverage on Stoke Therapeutics with a new price targetAnalyst resumed coverage of Stoke Therapeutics with a rating of Overweight and set a new price target of $40.00
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry converted options into 10,000 shares and sold $152,690 worth of shares (4,767 units at $32.03), increasing direct ownership by 26% to 25,655 units (SEC Form 4) to satisfy withholding tax4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERDirector Kaye Edward M. Md converted options into 26,250 shares and sold $402,528 worth of shares (12,567 units at $32.03), increasing direct ownership by 12% to 124,557 units (SEC Form 4) to satisfy withholding obligation4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERGENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 6,000 shares and sold $91,639 worth of shares (2,861 units at $32.03), increasing direct ownership by 17% to 21,225 units (SEC Form 4) (tax withholding)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $32.13 per share, which is equal to the closing price of S
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry sold $208,385 worth of shares (7,176 units at $29.04) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 20,422 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth ConferenceStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website at https://investor.stoket
- SECSEC Form 8-K filed by Stoke Therapeutics Inc.8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- SECSEC Form 424B5 filed by Stoke Therapeutics Inc.424B5 - Stoke Therapeutics, Inc. (0001623526) (Filer)
- SECSEC Form S-8 filed by Stoke Therapeutics Inc.S-8 - Stoke Therapeutics, Inc. (0001623526) (Filer)
- SECSEC Form 10-Q filed by Stoke Therapeutics Inc.10-Q - Stoke Therapeutics, Inc. (0001623526) (Filer)
- SECStoke Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- PRStoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates– Phase 3 EMPEROR study of zorevunersen in Dravet syndrome: Enrollment of 162 patients complete with data readout anticipated in Q3 2027 – – Pre-NDA meeting with FDA scheduled for H2 2026; rolling U.S. NDA submission planned to initiate in Q1 2027 – – Phase 1 OSPREY study of STK-002 in patients with ADOA: Dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027 – – $420M in cash, cash equivalents and marketable securities based on $354.3M as of June 30, 2026 and $65.7M from a subsequent ATM sale; expected to fund operations through to potential U.S. commercialization of zorevunersen in early 2028 – – Webcast and conference call for analy
- PRStoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial UpdatesStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Monday, August 3, 2026, at 4:30 p.m. ET, to discuss second quarter 2026 business and financial updates. The webcast will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the call
- INSIDERSEC Form 4 filed by Director Harrison Seth Loring4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Mccauley Thomas4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mccauley Thomas3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on July 15, 2026, it granted stock options to purchase shares of common stock to Thomas McCauley, the Company’s newly-appointed Chief Scientific Officer, and seven other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted Mr. McCauley stock options to purchase 225
- ANALYSTGoldman initiated coverage on Stoke Therapeutics with a new price targetGoldman initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $44.00
- PRStoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer–Dr. McCauley brings more than 25 years of experience building high-performing R&D organizations and translating early scientific discoveries into new medicines for people with severe diseases– Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Thomas McCauley, Ph.D., has been appointed Chief Scientific Officer. Dr. McCauley joins Stoke with more than 25 years of experience leading high-performing R
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry sold $236,068 worth of shares (7,228 units at $32.66) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 27,598 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SECSEC Form 8-K filed by Stoke Therapeutics Inc.8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- PRStoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome—Company plans to initiate a rolling U.S. NDA submission to the FDA in the first quarter of 2027— —Phase 3 data readout anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second half of 2027— Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen. Stoke plans to initiate a rolli
STOK FAQ
7 questionsWhat does Stoke Therapeutics Inc. do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera...Where does STOK stock trade?
Stoke Therapeutics Inc. (STOK) is listed on NASDAQ.What sector and industry is STOK in?
Stoke Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Stoke Therapeutics Inc. go public?
Stoke Therapeutics Inc. (STOK) completed its IPO in 2019.What are analysts saying about STOK?
Stoke Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $4000.00 price target on 2026-08-21. Recent price targets range from $1800.00 to $4400.00.What companies are similar to STOK?
Notable peers in the same industry include GTHX (G1 Therapeutics Inc.), GRTX (Galera Therapeutics Inc.), MCRB (Seres Therapeutics Inc.). Compare STOK side-by-side with any of them on Quantisnow.How can I track STOK on Quantisnow?
Quantisnow aggregates Stoke Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STOK to receive live email and push alerts on every new disclosure.